ArticleHuman vaccines & immunotherapeutics2026

Safety and immunogenicity of a first-generation modified vaccinia virus Ankara-vectored SARS-CoV-2 vaccine candidate with mRNA-based booster vaccination: A phase 1 trial.

Anahita Fathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.